Avalyn Pharma Inc. Common Stock (AVLN) Stock Analysis & Investment Frameworks
Avalyn Pharma Inc. Common Stock (AVLN) stock analysis on Invetso. Review Avalyn Pharma Inc. Common Stock’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Avalyn Pharma Inc. Common Stock Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Avalyn Pharma Inc. Common Stock Key Financial Metrics
- Market Cap: $1.11B
- Revenue: $N/A
- ROE: -83.23%
- ROIC: -14.25%
- Dividend Yield: N/A
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.